AFT Pharmaceuticals Limited





End-of-day quote New Zealand S.E. 06:00:00 2024-06-23 pm EDT 5-day change 1st Jan Change
3 NZD +5.26% Intraday chart for AFT Pharmaceuticals Limited -5.96% -14.29%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
New Zealand Shares Flat; Scott Technology Adds Meat Cutter to Brand Portfolio MT
AFT Pharmaceuticals Partners with Alexso to Bring Pain Relief Drug to US Market MT
AFT Pharmaceuticals Limited to Launch Maxigesic Rapid in the United States CI
AFT Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Transcript : AFT Pharmaceuticals Limited, 2024 Earnings Call, May 23, 2024
AFT Pharmaceuticals' Net Profit Climbs 46% in Fiscal 2024; Dividend Declared MT
AFT Pharmaceuticals Limited Announces Ordinary Dividend for the Twelve Months Ended Mach 31, 2024, Payable on July 4, 2024 CI
AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV MT
AFT Pharmaceuticals Limited Licenses Maxigesic IV in Brazil CI
New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment MT
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment MT
AFT Pharmaceuticals Limited, Massey Ventures, Gilles Mcindoe Research Institute to Develop Scar Treatment CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals MT
Aft Expands Its Co-Operation with Hikma Pharmaceuticals CI
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024 MT
AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024 CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4% MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US MT
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus CI
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals CI
France keeps 2024 bond issuance steady at 285 bln euros RE
Chart AFT Pharmaceuticals Limited
More charts
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
3.75 NZD
Spread / Average Target

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. AFT Stock
  4. News AFT Pharmaceuticals Limited
  5. AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment